Exercise to Boost Response to Checkpoint Blockade Immunotherapy

Inclusion criteria

• Males and females ≥18 years of age.
• Able to read and speak English fluently.
• Reported ability to complete 20-30 minutes moderate exercise per positive response to, "Can you currently walk unaided for six minutes or more?"
• Scheduled for first-time checkpoint blockade immunotherapy with avelumab, cemiplimab, ipilimumab, nivolumab, or pembrolizumab in the absence of other therapies (e.g. targeted therapy) with the following diagnosis:

• Adjuvant setting: cutaneous melanoma.
• Neoadjuvant setting: cutaneous melanoma, cuSCC, or Merkel cell carcinoma.
• States willingness to follow protocol as described, including the prescribed exercise level and completing any forms needed throughout the study.
• Voluntarily signed and dated an informed consent form, approved by an Institutional Review Board/Independent Ethics Committee, and provided Health Insurance Portability and Accountability Act authorization (HIPAA) or other privacy authorization prior to any participation in study.

Exclusion criteria

• Presence of medical conditions, such as severe cardiovascular disease for which exercise may be contraindicated. Participants may be referred to their medical team to obtain a cardiology approval.
• Presence of major postoperative complications for which an exercise intervention may be contraindicated.
• Currently has a chronic, contagious, infectious disease, such as active tuberculosis, active Hepatitis B or C, HIV, or COVID-19, per self-report.
• Currently pregnant, lactating or planning to become pregnant (positive result on urine pregnancy testing).
• Presence of any condition that, in the opinion of the Investigator, compromises participant safety or data integrity or the participant's ability to complete the study.